Shattuck Labs

Shattuck Labs

Shattuck Labs launched in 2016 in Austin, Texas, with a research facility in Durham, North Carolina, founded by CEO Taylor Schreiber and Chairman Josiah Hornblower. The firm emerged from a period of intense scientific interest in TNF receptor superfamily agonism, aiming to build a next-generation immunotherapy platform. Its initial public offering on the Nasdaq in October 2020 raised approximately $230 million, positioning the company to advance multiple wholly owned clinical-stage programs. The founding thesis centered on ARC (Agonist Redirected Checkpoint) technology, which fuses an anti-TNF receptor agonist domain to a checkpoint inhibitor domain in a single molecule. Shattuck's strategy concentrates on direct investment in clinical-stage oncology and immunology assets, with a sharp focus on the TNF superfamily. The firm advanced a set of wholly owned programs, including SL-172154, an ARC fusion targeting CD47 and CD40, which entered multiple Phase 1 and Phase 2 trials for indications such as acute myeloid leukemia and platinum-resistant ovarian cancer. A second leading program, SL-279252, targeted PD-1 and OX40. By late 2023, however, strategic prioritization led to a significant pipeline cull. Shattuck discontinued SL-279252 and its OX40 program, consolidated around the CD40 agonist platform, and advanced a DR3 agonist into clinical trials for inflammatory bowel disease. The firm's deployment is concentrated in the United States, with clinical trial sites extending to Canada and Europe. Shattuck operates as a public biotechnology company with a lean executive team led by Schreiber. In December 2023, the firm announced a strategic shift to focus solely on SL-172154 in oncology and SL-325 in immunology, stopping work on its foundational PD-1 combination platform. This restructuring included a workforce reduction to extend the company's cash runway into 2027. The firm's balance sheet and public-market access replaced the traditional venture-capital syndicate model, though early private investors included Hatteras Venture Partners and NEA. Shattuck has no disclosed philanthropic or multi-family-office adjacent vehicles. Shattuck's structural differentiator lies in its public-company architecture applied to a single-platform, pre-revenue biotech model. This forces a stark capital-allocation discipline: the firm must choose between deploying capital into clinical trials, platform research, or returning cash to shareholders. The 2023 decision to abandon its ARC platform's foundational checkpoint combination hypothesis in favor of two monotherapy programs represents a governance choice uncommon in venture-backed private biotechs, where broader platform exploration often continues longer. The firm's fate now rests on a binary bet — CD40 agonism and DR3 agonism — with no diversification across therapeutic modalities.